ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2608

Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis
Abstract Number: 2303

Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
Abstract Number: 0322

Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 2002

Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk
Abstract Number: 2115

METHOFRACT, a methotrexate osteopathy multicentric binational cohort study.
Abstract Number: 2576

Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time
Abstract Number: 2682

Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
Abstract Number: 0891

MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial.
Abstract Number: 2429

mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
Abstract Number: 1119

Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Abstract Number: 0054

Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
Abstract Number: 2643

Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy
Abstract Number: 0800

Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production
Abstract Number: 2501

Microvascular dysfunction contributes to hand bone deterioration in SSc patients
Abstract Number: 1332

Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].